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Abstract
Background: Urinary incontinence (UI) is highly prevalent in nursing and residential care homes (CHs) and
profoundly impacts on residents’ dignity and quality of life. CHs predominantly use absorbent pads to contain UI
rather than actively treat the condition. Transcutaneous posterior tibial nerve stimulation (TPTNS) is a non-invasive,
safe and low-cost intervention with demonstrated effectiveness for reducing UI in adults. However, the
effectiveness of TPTNS to treat UI in older adults living in CHs is not known. The ELECTRIC trial aims to establish if a
programme of TPTNS is a clinically effective treatment for UI in CH residents and investigate the associated costs
and consequences.
Methods: This is a pragmatic, multicentre, placebo-controlled, randomised parallel-group trial comparing the
effectiveness of TPTNS (target n = 250) with sham stimulation (target n = 250) in reducing volume of UI in CH
residents. CH residents (men and women) with self- or staff-reported UI of more than once per week are eligible to
take part, including those with cognitive impairment. Outcomes will be measured at 6, 12 and 18 weeks post
randomisation using the following measures: 24-h Pad Weight Tests, post void residual urine (bladder scans),
Patient Perception of Bladder Condition, Minnesota Toileting Skills Questionnaire and Dementia Quality of Life.
Economic evaluation based on a bespoke Resource Use Questionnaire will assess the costs of providing a
programme of TPTNS. A concurrent process evaluation will investigate fidelity to the intervention and influencing
factors, and qualitative interviews will explore the experiences of TPTNS from the perspective of CH residents, family
members, CH staff and managers.
Discussion: TPTNS is a non-invasive intervention that has demonstrated effectiveness in reducing UI in adults. The
ELECTRIC trial will involve CH staff delivering TPTNS to residents and establish whether TPTNS is more effective than
sham stimulation for reducing the volume of UI in CH residents. Should TPTNS be shown to be an effective and
acceptable treatment for UI in older adults in CHs, it will provide a safe, low-cost and dignified alternative to the
current standard approach of containment and medication.
Trial registration: ClinicalTrials.gov, NCT03248362. Registered on 14 August 2017.
ISRCTN, ISRCTN98415244. Registered on 25 April 2018. https://www.isrctn.com/.
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Introduction
Background and rationale
The highest prevalence of urinary incontinence (UI), de-
fined by the International Continence Society as ‘any in-
voluntary loss of urine’ [1], is found in residential or
nursing care homes (CHs). UI is distressing for older
adults and profoundly impacts on dignity and quality of
life [2]. It is associated with impaired physical function-
ing [3], cognitive impairment [3, 4], sleep disturbance
[2], falls [5, 6], fractures [7], urinary tract infection (UTI)
[8] and hygiene and tissue viability problems [9]. UI af-
fects social participation and is a major cause of clinical
depression and social isolation [10, 11]. UI is costly to
CH providers, healthcare services and the individual
older adult. Direct personal and treatment costs are
high. Intangible costs associated with social isolation and
withdrawal from community participation also occur
[10] but have not been quantified.
The most common type of UI experienced by older
CH residents is mixed UI, combining symptoms of over-
active bladder (OAB): urgency, frequency, nocturia with
or without urgency UI, with stress UI [12]. For most this
is exacerbated by functional losses of urine associated
with frailty [13]. No evidence of the effects of conserva-
tive interventions directly addressing mixed incontinence
in CH populations is yet available [12]. There is also a
dearth of published evidence on interventions to pro-
mote recovery of bladder continence in the CH context
[14] or for people living with dementia, even though the
CH population is three times more likely to have UI or
faecal incontinence (FI) than people of equivalent age
and characteristics [15]. The burden of UI in the CH
population is significant and increasing [3], yet evidence
suggests that even intractable UI is amenable to inter-
ventions that may improve urinary function and quality
of life [16]. Currently CHs use containment approaches,
predominantly absorbent pads, rather than active treat-
ment as the mainstay for managing UI [8]. Other non-
pharmacological options include bladder training [17]
and pelvic floor muscle training [18] as well as toileting
programmes, signage and environmental adaptations for
people with dementia. However, evidence indicates these
are rarely used, have limited effectiveness in the CH en-
vironment and are labour intensive [19], which impacts
on sustainability in the longer term. They also require a
degree of cooperation, engagement and activity by the
resident, which can be prohibitive for people with cogni-
tive impairment [14, 20]. Antimuscarinic drugs may be
used to reduce urge/OAB problems; however, these
drugs are associated with significant adverse effects in
frail older people and should be avoided in those with
dementia, as they may also counteract the functional
benefits of anticholinesterase inhibitors [21]. Newer β3-
adrenergic receptor agonist drugs with potential benefit
such as mirabegron are available, but the frail CH popu-
lation has not been included in drug trials and, with
prevalent polypharmacy in such contexts, any additional
medication may increase adverse effects [22].
Transcutaneous posterior tibial nerve stimulation
(TPTNS) is a simple, non-invasive, safe and low-cost
intervention with promising effectiveness, directly target-
ing urgency or mixed UI [23, 24]. It uses a portable
transcutaneous electrical nerve stimulation (TENS) ma-
chine to stimulate the posterior tibial nerve using surface
electrodes placed adjacent to the medial malleolus. It
does not require the resident to actively engage in order
to receive the intervention, and so is suitable for those
who are physically and cognitively frail. It is comfortable
to use [25] and promotes dignified care, as only access
to the resident’s ankle is required. It has been shown in
randomised controlled trials (RCTs) to reduce UI in
community-living older women [24] and adults with
neurogenic bladder dysfunction (including multiple
sclerosis [26], Parkinson’s [27] and stroke [28]); however,
no definitive RCTs have focused on treating UI in the
CH population. A small randomised feasibility study in-
dicated the safety, acceptability and potential effects of
TPTNS in this context [23].
Although the exact mechanism of action has yet to be
fully understood, TPTNS is believed to restore the bal-
ance between excitatory and inhibitory bladder function-
ing by modulating the signal traffic to and from the
bladder through the sacral plexus [29]. It is hypothesised
that stimulating afferent sacral nerves in the lower ex-
tremities increases the inhibitory stimuli to the efferent
pelvic nerve, suppresses bladder afferent nerve activity,
reduces detrusor contractility and increases bladder cap-
acity [30], and by these means TPTNS reduces the sen-
sation of urgency and the frequency of micturition, thus
enabling improved bladder control. These mechanisms
may also reduce the volume of urine retained in the
bladder after voiding [23, 26]. For the CH residents who
wear absorbent pads because of mixed/urgency UI,
TPTNS may reduce the sudden urge to urinate and fre-
quency of voiding, allowing residents more time to reach
the toilet, which in turn will enable more appropriate
use of the toilet, generating respect and enhancing the
person’s dignity.
As a potentially therapeutic modality, TPTNS could
occupy a unique position in the CH care pathway for UI,
as it provides active treatment of the mixed/urgency UI
condition without requiring any active contribution by
the resident. Thus, unusually, it is as likely to be of bene-
fit to those with cognitive impairment as those without,
and has been shown to be safe and not associated with
any severe or limiting adverse effects. Skin redness and
potential skin allergy are the only mild adverse effects
reported.
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A systematic review of TPTNS for UI identified ten
RCTs [31]. A total of 472 participants were included,
only 30 of whom were from a single CH population. All
studies reported improvements in bladder condition
with TPTNS, in terms of symptom improvement and/or
UI-related quality of life, although no one trial was de-
finitive. A meta-analysis (two trials) found a mean differ-
ence between TPTNS and control group in the self-
reported International Consultation on Incontinence
Questionnaire-Urinary Incontinence (ICIQ-UI) short-
form score of − 3.79 (95% confidence interval [CI] –
5.82, – 1.76), which was considered a clinically meaning-
ful effect [32]. There were no significant adverse events
(AEs), and TPTNS was consistently reported as safe.
However, the studies in the meta-analysis were small
(outcomes from 79 participants), with methodological
weaknesses and a Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) [33] rating of
‘low quality’. With the increases in the older adult popula-
tion and concomitant multimorbidities including dementia
[16], together with the associated increase in numbers with
UI, especially OAB/urgency incontinence [3, 12], there is a
pressing need to investigate interventions to treat UI to
reduce the burden on CH residents and care providers.
Objectives
The ELECTRIC trial will:
1. Establish whether TPTNS is more effective than
sham stimulation for reducing the volume of UI at
6, 12 and 18 weeks, in CH residents
2. Investigate mediating factors that impact on the
effectiveness of TPTNS in a mixed method, process
evaluation involving fidelity assessment,
implementation support and qualitative
components
3. Undertake economic evaluation of TPTNS in CHs
assessing the costs of providing the programme and
presenting the findings alongside the key primary
and secondary outcomes in a cost consequence
analysis
4. Explore in an interview study the experiences of
TPTNS from the perspectives of:
 CH residents
 Family carers
 CH nurses and senior carers
 CH managers.
Trial design
The research comprises a pragmatic, multicentre, placebo-
controlled randomised parallel-group trial to compare the ef-
fectiveness of TPTNS (target n= 250) with sham stimulation
(target n= 250) to reduce volume of UI in CH residents. Re-
sults from an internal pilot with 100–140 residents will
determine progression to the main trial. A longitudinal,
mixed methods nested process evaluation will run in parallel
with the RCT to investigate intervention fidelity and accept-
ability, as well as qualitative exploration of the intervention
delivery and implementation support. An economic evalu-
ation of TPTNS compared with usual continence care will
be completed in the form of a cost consequence analysis.
The trial is designed in accordance with the Standard Proto-
col Items: Recommendations for Interventional Trials
(SPIRIT) checklist (see Additional file 3).
Methods: participants, interventions and
outcomes
Study setting
The settings will be CHs (nursing or residential) for
older adults in England and Scotland.
Eligibility criteria
The inclusion criteria are described as follows. CH resi-
dents will be eligible for inclusion if they have self- or
staff-reported UI more than once per week; if they use
the toilet or a toilet aid for bladder emptying with or
without assistance; and if they wear absorbent pads to
contain urine.
Exclusion criteria include CH residents who:
1. Have an indwelling urinary catheter
2. Have symptomatic UTI
3. Have post void residual urine (PVRU) volume more
than 300 ml
4. Have a cardiac pacemaker
5. Have treated epilepsy
6. Have bilateral leg ulcers
7. Have pelvic cancer (current)
8. Are in palliative care status
9. Are non-English speakers.
Who will take informed consent?
Processes for identifying eligibility and participant re-
cruitment will differ in England and Scotland according
to relevant legislation on capacity to provide informed
consent to participate. In both countries the local Princi-
pal Investigator (PI, senior clinical nurse or manager) in
each CH will identify potentially eligible residents, pro-
vide study information to all those with capacity and
seek agreement from the residents for them to be
approached by the Regional Research Assistant (RRA-
registered nurses working in trial regions in Scotland
and England) to receive further information about the
study. All resident recruitment will be undertaken by the
RRAs. In CHs in England in accordance with the Mental
Capacity Act 2005 [34], where the local PI believes a res-
ident’s capacity is in question, they will identify and pro-
vide the information to the resident’s personal consultee
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(usually a family member or friend), or if one is not
available, a nominated consultee identified by the CH
study team, and seek their agreement for an approach
from the RRA. The RRA will provide a full explanation
of the study, ensure eligibility and seek the consultee’s
advice on what they feel the resident’s wishes would be
about taking part in the trial, if they had capacity. The
consultee will sign a declaration form if they believe the
resident would choose to agree to participate. In CHs in
Scotland, in accordance with the Adults with Incapacity
(Scotland) Act 2000 [35], where a resident has a certifi-
cate of incapacity the local PI will identify and provide
the study information to the resident’s welfare attorney
(if one has been appointed) or their nearest relative. If
there is no welfare attorney identified, or the resident
does not have a relative who can be consulted, they will
be considered ineligible to participate in the study. The
local PI will seek agreement from the welfare attorney/
nearest relative for the RRA to speak to them. The RRA
will provide a full explanation of the study to the welfare
attorney/nearest relative, ensure eligibility and seek writ-
ten consent for the resident to participate. Written con-
sent to participate in the process evaluation interviews
will be sought by the RRA from the individual family
carers or CH staff prior to the resident taking part.
Additional consent provisions for collection and use of
participant data and biological specimens
On the consent form, participants will be asked if they
agree to use of their data should they choose to with-
draw from the trial. Participants will also be asked for
permission for the research team to share relevant data
with people from the universities taking part in the re-
search or from regulatory authorities, where relevant.
This trial does not involve collecting biological speci-
mens for storage.
Interventions
Explanation for the choice of comparators
To ensure the resident and their relatives are blind to
the allocated intervention group, a sham stimulation
intervention rather than a no-treatment comparator
will be used. The sham stimulation will comprise
low-intensity, subclinical stimulation of the lateral
submalleolar area, positioned specifically on the lateral
aspect of the ankle in order to avoid the tibial nerve,
which runs close to the skin surface behind the med-
ial malleolus. The cathode electrode will be positioned
behind the lateral malleolus and the anode 10 cm
cephalad to it. The stimulation parameters will be
identical to the TPTNS stimulation other than the in-
tensity of the current, which will always be set at 4
mA, not adjusted to individual comfort levels as it is
in the TPTNS intervention group. The current will be
initially increased until the resident reports feeling
some sensation, following which the current will be
reduced to 4 mA. All residents will be informed that
they may not feel anything with this intervention and
that this is quite normal. A previous pilot study [23]
found that older residents were unable to accurately
identify their allocated group and confirmed the in-
tegrity of the sham stimulation protocol.
Intervention description
TPTNS is a form of peripheral neuromodulation. The
tibial nerve, which lies immediately posterior to the
medial malleolus, will be stimulated electrically using a
portable TENS machine and two surface electrodes. The
cathode electrode will be positioned behind the medial
malleolus and the anode 10 cm cephalad to it. Standar-
dised stimulation parameters will be applied of 10 Hz
frequency, and a pulse width of 200 μs, in continuous
stimulation mode. Intensity of stimulation (mA-1) will be
adjusted on a session-by-session basis according to indi-
vidual resident highest tolerated intensity below the
motor threshold that remains comfortable. Both inter-
vention and placebo/sham groups will receive an elec-
trical stimulation programme comprising a total of 12
sessions of 30 min duration each, delivered twice weekly
over 6 weeks. The stimulation equipment and method of
delivery will be identical in everything but the intensity
of electrical stimulation applied and the positioning of
the surface electrodes. The electrical stimulators will be
programmed to the set parameters and locked prior to
individual use so that the only adjustable parameter will
be the intensity of stimulation. The intervention will be
delivered by CH registered nurses and senior carers who
will receive specific training and support to undertake
this role. No strict TPTNS/sham intervention timetable
will be set, and individual CHs will have flexibility
around where, how and when they deliver the sessions,
bearing in mind that they should occur twice weekly for
30 min each, over a 6-week period. A proposed schedule
for each home and resident will be agreed between the
resident, registered nurse/senior carer and local PI at the
point of treatment inception. The allocated treatment
(TPTNS or sham) will be offered to the resident a max-
imum of two times in any 24-h period. If refused when
first offered (verbally or by non-verbal behaviour), the
treatment will be postponed for at least an hour and then
offered one further time. Records of acceptance and refusals
will be documented in the resident’s treatment diary.
Adherence to the TPTNS or sham stimulation programme
will be one of the progression criteria to full-scale trial from
the internal pilot. While aiming to complete a full 12-
session programme over the 6-week intervention period,
contingency measures will be implemented if four or more
sessions are refused or missed by the resident. Such
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measures will include approaching the resident at a later
time, a different place or on a different day.
Criteria for discontinuing or modifying allocated
interventions
There will be no special criteria for discontinuing or
modifying allocated interventions. Residents will remain
in the trial unless they (or their welfare attorney/nearest
relative in Scotland) choose to withdraw consent, or if
their personal or nominated consultee (in England) ad-
vises that they believe the person’s wishes about partici-
pation have changed, or they are unable to continue for
a clinical reason or if they die.
Strategies to improve adherence to interventions
An individual resident stimulation diary will be com-
pleted by the registered nurse/senior carer following
each session, recording date, time, intensity of electrical
stimulation and any comments on the process of deliv-
ery. The locked stimulation machines will automatically
record the total stimulation time in use and the average
stimulation intensity of all recorded sessions, thus pro-
viding an objective record of the stimulation programme
provided to each resident. This recorded data will be
compared against the individually written stimulation
diary completed by the staff after each session. The fidel-
ity comparison will be performed by an Implementation
Support Facilitator (ISF) whose role will be to provide
support and ongoing training to CH staff and ensure they
are competent and confident to deliver the stimulations.
Electrode positioning, indicating accuracy of the allocated
intervention, will be recorded using a digital photograph
taken by staff every 2 weeks during the intervention
delivery period, and will be viewed by the ISF.
Relevant concomitant care permitted or prohibited
during the trial
Implementing TPTNS or sham stimulation will not re-
quire alteration to current continence care pathways (in-
cluding use of any medication), and these will continue
in line with CH policies for both trial arms.
Provisions for post trial care
Each participating CH will be provided with electrical
stimulator machines after the trial follow-up period has
been completed, should the homes wish to continue use
of TPTNS.
Outcomes
Table 1 summarises the outcomes assessed at baseline
and at the 6 weeks, 12 weeks and 18 weeks post ran-
domisation assessments.
Primary outcome measure
The primary outcome is the volume of urine leaked over
a 24-h period at 6 weeks post randomisation.
Secondary outcome measures
Secondary urinary outcome measures are as follows:
 Volume of urine leaked over a 24-h period at 12 and
18 weeks post randomisation
Table 1 Outcomes assessed at trial time points
Baseline 6-week 12-weeks 18weeks Data collector
24 hour PWTa ● ● ● ● CH staff and RRA
Number of pads used ● ● ● ● RRA
72 hour bladder diary ● ● ● ● CH staff
PVRUb ● ● ● ● RRA
PPBCc ● ● ● ● Resident and RRA
FC-PBCd ● ● ● ● Family member
S-PBCe ● ● ● ● SC/RN responsible for care provision
MTSQf ● ● ● ● Resident and RRA
MTSQf ● ● ● ● CH staff and RRA
DEMQOLg ● ● ● Resident and RRA
DEMQOL-proxyh ● ● ● Single, named proxy and RRA
Resource Use Questionnaire ● ● ● RRA
aPad Weight Test
bPost Void Residual Urine volume
cPatient Perception of Bladder Condition
dFamily Carer Perception of Bladder Condition
eStaff Perception of Bladder Condition
fMinnesota Toileting Skills Questionnaire
gMeasure of health-related quality of life in people with dementia (resident)
hMeasure of health-related quality of life in people with dementia (proxy)
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 Number of pads used in 24 h at 6, 12 and 18 weeks
post randomisation
 PVRU at 6, 12 and 18 weeks post randomisation
 The Patient Perception of Bladder Condition [36]
(PPBC) at 6, 12 and 18 weeks post randomisation
 The Minnesota Toileting Skills Questionnaire [37]
(MTSQ) at 6, 12 and 18 weeks post randomisation.
Quality of life outcomes
The quality of life outcome measures are:
 Resident Dementia Quality of Life (DEMQOL) [38]
at 6 and 18 weeks post randomisation
 For those not able to complete it themselves, a
proxy DEMQOL [38] at 6 and 18 weeks post
randomisation.
Economic outcomes
For economic outcomes, the Resource Use Question-
naire (RUQ) (Additional file 2) will be applied at 6 and
18 weeks post randomisation
Participant timeline
See Fig. 1 for the resident flowchart.
Sample size
A total of 500 residents will be recruited. It was believed
that the intervention may result in a worthwhile differ-
ence of a reduction of 200ml/24 h in UI, equivalent to
200 g in pad weight [39]. There is a lack of data available
on the standard deviation (SD) of Pad Weight Tests [40]
(PWTs) in CH residents; however, a small RCT [39] re-
ported results on this outcome. The SD from the trial
was 450ml, but given the small and selected sample in-
cluded, the upper 95% CI around the SD was estimated
and found to be approximately 570 ml/24 h, hence
resulting in a standardised effect size of 0.35 (i.e. 200/
570). To detect that difference with 90% power at the
two-sided 5% alpha level, primary outcome data on 344
participants will be required. The limited data available
suggested that the intra-class correlation (ICC) for any
possible clustering effect was likely to be negligible.
However, the sample size will be inflated to 500 to com-
pensate for attrition in the primary outcome due to
death of CH residents and potential transfers to other
CHs, estimated conservatively to be 30% [40].
Recruitment
CHs with a minimum of 25 residents will be eligible to
take part. The minimum population of residents will be
1700, although the expected number will be considerably
higher. Approximately 70% will have UI, and 10% will be
in receipt of palliative care or do not use the toilet/toilet
aid for elimination. Thus, there will be an estimated
minimum total pool of 1071 eligible residents from whom
500 will be recruited. Assuming similar recruitment rates
to the Health Technology Assessment (HTA)-funded De-
mentia Care Mapping (DCM)-EPIC study undertaken in
CHs of 60% of eligible CH residents [41], this would pro-
vide at least 643 residents from whom to recruit a sample
of 500. Recruitment will be undertaken over an 18-month
period, commencing with month 6 and completed by
month 24. At least four new CH sites will be established
every 3months during the recruitment period, depending
on CH size and location.
Assignment of interventions: allocation
Sequence generation
Eligible, consenting residents are randomised to one of
the two groups (TPTNS or sham). Randomisation is
computer allocated on a one-to-one basis in random
permuted blocks of size two, four or six, with stratifica-
tion by:
 Sex (male/female)
 UI severity (mild [0–200 ml/24 h]; moderate [200–
400 ml/24 h]; severe [400+ ml/24 h])
 Centre (CH).
Concealment mechanism
Randomisation will utilise a proven web-based random-
isation system, hosted by the Centre for Healthcare Ran-
domised Trials (CHaRT) Unit, which ensures allocation
concealment.
Implementation of allocation sequence
The allocation sequence generation will be embedded in
the trial website. After participants are enrolled, their
baseline information will be entered onto the randomisa-
tion database remotely by the RRAs. The randomisation
results will be automatically generated and emailed to
the ELECTRIC trial office, who will forward them to the
relevant local PI.
Assignment of interventions: blinding
Who will be blinded
Information required to perform the randomisation will
be submitted by the RRA who obtained the consent.
However, to ensure the RRA is blinded to group alloca-
tion, the information on the allocated group will be de-
livered to the local PI in each CH by the ELECTRIC trial
office, who will receive the allocation information from
CHaRT. The local PI will record the allocated group in a
separate file and inform the CH staff who will deliver
the allocated intervention.
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Procedure for unblinding if needed
We do not anticipate any requirement for unblinding,
but if required, the Trial Manager, Data Coordinator,
ISFs and CH managers will have access to group alloca-
tions, and any unblinding will be reported.
Data collection and management
Plans for assessment and collection of outcomes
Outcomes will be measured at 6, 12 and 18 weeks post
randomisation. The primary outcome is the volume of
urine leaked in 24-h at 6 weeks post randomisation, as
Fig. 1 Resident flowchart
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measured by a 24-h PWT [40]. PWTs at 12 and 18
weeks measure the sustainability of any effect. The test
is based on the premise that 1 g fluid weight = 1 ml
urine and is thus an objective measure of urine leakage.
The PWT involves the resident emptying their bladder,
applying a clean, dry pad at an agreed set time and
retaining all pads used between this time and 24 h later.
To maintain the moisture in the removed pads and pre-
vent evaporation, all collected pads will be individually
sealed in a small plastic bag and then placed in a larger
re-sealable bag, which is weighed onsite by the RRA
after the 24-h collection ends. The dry weight of the
equivalent pads to those collected will be deducted
from the total weight to provide the 24-h volume of UI
leaked. Secondary outcome measures will include the
number of pads used in 24 h, which may be expected to
reduce if TPTNS is effective in reducing volume of UI
and will be reflected in the economic evaluation.
PVRU will be measured using a non-invasive portable
ultrasound bladder scanner. A pilot study conducted
with CH residents [23] suggested a potential mean de-
crease of 55 ml in PVRU following a TPTNS programme
compared to the sham stimulation group. It is thus
worth investigating whether this was an artefact, or
whether TPTNS impacts on urinary retention in the frail
older adult population. Additionally, it is important to
ensure that any effect of TPTNS in reducing bladder
leakage is not as a result of an increase in retained urine
volume.
The PPBC [36] is a single-question global patient-
reported outcome measure of perceived bladder condi-
tion with six possible responses, ranging from ‘My blad-
der condition does not cause me any problems at all’ to
‘My bladder condition causes me many severe problems’.
It has good construct validity and responsiveness to
change [36] and is recommended as a global outcome
measure for UI [37]. It will be used at each time point
with residents. However, it will also be adapted in this
study for use by family carers as the Family Carer Per-
ception of Bladder Condition (FC-PBC) and by the CH
staff as the Staff Perception of Bladder Condition (S-
PBC) to offer a perspective on how they believe the resi-
dent feels about their bladder condition.
The MTSQ [37] is a five-question patient-reported
outcome measure of degree of difficulty on a scale of 0
to 4 for completing five tasks involved in toileting.
Scores range from 0 to 20, with higher scores indicating
more difficulty. The MTSQ is a reliable and valid
interviewer-administered measure of toileting skills in
physically frail older women [37]. It will be completed at
all time points by the resident and/or staff member.
Quality of life is measured using the DEMQOL and
DEMQOL-Proxy [38], valid and reliable measures of
health-related quality of life in people with dementia. The
DEMQOL-Proxy will be completed by a single identified
proxy for the resident. Both measures will be completed at
the primary outcome point (6 weeks post randomisation)
and at the 18 weeks follow-up assessment.
Economic evaluation will be undertaken using routine
data available in CHs as well as information from the
RUQ designed for this study (Additional file 2). The
RUQ will be administered by the RRA, who will record
at baseline the usual continence care pathway including
details on usage of pads and other equipment, medica-
tion which may affect continence level and (if appropri-
ate) number of staff required to assist residents to use
the toilet. At the primary outcome point (6 weeks) and
at the 18 weeks follow-up time point, the RRA will use
the RUQ, in combination with the 24-h bladder diary, to
update the continence care pathway. If residents have re-
quired any care from health professionals external to the
CH as a result of their UI, this is also recorded on the
RUQ. Staff time required for training and the delivery of
the intervention will be recorded by each CH, including
the number of hours and the staff grade.
Process evaluation
The longitudinal process evaluation will be undertaken
concurrently with the RCT and will primarily involve
undertaking qualitative interviews with a range of infor-
mants (Table 2). The objectives will be to explore the ex-
periences of the TPTNS intervention from the
perspectives of residents, family carers and CH staff and
to explore factors affecting intervention implementation
in the CH context and optimisation for sustainability.
Additionally, data on stimulation time and intensity with
individual residents will be automatically recorded by the
stimulation machines, which will be allocated for use by a
single resident only, in order to ensure accurate informa-
tion on stimulation is collected. This objective information
will be compared with diary information completed by
staff.
Qualitative data collection
Qualitative interviews will be undertaken by a research
assistant skilled in the application of qualitative methods
and will explore experiences of TPTNS or sham stimula-
tion and any perceived impact on continence status and
quality of life from the perspective of the CH residents
and their family carers. Attention will be given to under-
standing the intervention acceptability in the short and
longer term, especially in comparison to other UI man-
agement strategies they may be familiar with, and the
identification of potential adherence moderating factors
for future TPTNS delivery. All interviews will be digitally
recorded and transcribed verbatim in preparation for
analysis.
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For resident and/or family carer interviews, face-to-
face semi-structured interviews will be undertaken with
residents and/or family carers, either as individual inter-
views or dyads. A total of 20 interviews will be carried
out at 6 weeks, on completion of the intervention. A
maximum of 20 further interviews with different resi-
dents/carers will take place at the 12-week juncture. Pur-
posive sampling of resident/carers for the qualitative
interviews will be undertaken on the basis of maximum
variability sampling [42] with regard to gender, age,
bladder symptoms, cognitive and functional status and
resident or carer status. Three quarters of the interviews
will involve residents who have received the TPTNS
intervention or their families. A topic guide for the
semi-structured approach will be developed to ensure all
questions of interest are addressed. Fewer interviews will
be conducted if data saturation is reached.
For CH nurses/senior carer interviews, focus group (or
small group) interviews will be undertaken with CH
nurses and senior carers involved in the direct delivery
of the TPTNS/sham intervention. Attention will be paid
to understanding the organisation of care, how manage-
ment works with care staff, level of staff turnover in the
previous 6 months and how continence care is organised
within the routines of the CH. One focus group per CH
or, where for staffing reasons this is not possible to or-
ganise, two to three small group interviews, will be held
during the month following the intervention completion.
This will result in the equivalent of 20 focus group inter-
views involving 60–100 CH staff. Additionally, up to 20
individual interviews will be undertaken with nurses/se-
nior carers delivering the intervention, to explore and
elicit views which staff may be reluctant to share in a
group interview.
Regarding the CH managers, individual telephone in-
terviews with them (n = 20) will be completed at the end
of each CH’s involvement with the study (6 months fol-
lowing site inception). The focus of these interviews will
be to explore the CH culture and management values as
well as perceived effects of the continence intervention
at the organisational level, including any impact on cul-
ture and quality of care and any economic effects. Stra-
tegic considerations for implementation rollout and
sustainability in the event that TPTNS is found to be ef-
fective will be identified and explored in depth.
Plans to promote participant retention and complete
follow-up
The CH resident population is relatively stable, with changes
being largely the result of individual illness or death;
therefore, discontinuation or change of status is anticipated
rather than loss to follow-up. The collection of outcomes
will be undertaken by a single RRA in each CH, who will be
well known to the CH staff, and it is anticipated this design
will support good retention and follow-up rates.
Data management
Both paper-based and electronic data entry will be used.
Data will be collected locally by the RRA and entered
onto the database for screening and randomisation pur-
poses. Paper-based Case Report Form (CRF) data will be
delivered securely to the trial office for data entry.
Confidentiality
All collected information will be kept strictly confiden-
tial and will be stored in accordance with the UK Data
Protection Act 2018 [43] and retained in accordance
with the latest Directive on Good Clinical Practice
Table 2 Process evaluation data collection
Process evaluation data collection Focus of questioning/data collection
Resident (with and without capacity) and/or family
carer interviews at 6 weeks (n = 20)
Experiences, impact and acceptability
Resident (with and without capacity) and/or family
carer interviews at 12 weeks (n < 20)
Experiences of incontinence, impact
and acceptability of TPTNS
CH nurses/senior carer focus group interviews at
4–6 months (n = 20, number of participants 60–100)
Organisation and care home provision
of continence care and influencing factors
CH nurses/senior carer individual interviews at 4–6
months (n < 20)
Organisation and care home provision of
continence care and influencing factors
CH managers individual telephone interviews (n = 20) Care home culture, management values, perceived
impact of continence intervention at the
organisational level, economic effects. Strategic
considerations for implementation, rollout and
sustainability
Fidelity to group allocation monitoring Digital photographs of electrode position and
stimulation diaries completed by staff
Adherence to stimulation programme Objective recording of stimulation time and average
intensity and stimulation diaries completed by staff
24-h bladder diaries Patterns of voiding and toilet use
Booth et al. Trials          (2019) 20:723 Page 9 of 14
(GCP) and local policy. Data collected during the course
of the research will be kept strictly confidential and only
accessed by members of the trial team (or individuals
from the Sponsor organisation or CH sites where rele-
vant to the trial). Participants will be allocated an indi-
vidual trial identification number. Participants’ details
will be stored on a secure database under the guidelines
of the 2018 General Data Protection Regulation (EU)
2016/679 [44]. The CHaRT senior IT manager (in col-
laboration with the Chief Investigator [CI]) will manage
access rights to the data set. It is anticipated that anon-
ymised trial data may be shared with other researchers
to enable international prospective meta-analyses.
Plans for collection, laboratory evaluation and storage of
biological specimens for genetic or molecular analysis in
this trial/future use
This aspect is not applicable; there are no biological
specimens.
Access to data
Data may be available for collaborators on request to the
CI.
Analysis
Statistical methods for primary and secondary outcomes
All analyses will be undertaken according to a previously
agreed statistical analysis plan (SAP), which will be
agreed with the Trial Steering Group (TSC), including
the independent statistician, before the database is
locked and any data analysis commences.
Main effectiveness analysis
All baseline characteristics, follow-up measurements and
safety data will be described using the appropriate de-
scriptive summary measures: mean and SD for continu-
ous and count outcomes or medians and inter-quartile
range if required for skewed data, numbers and percent-
ages for dichotomous or categorical outcomes. The pri-
mary outcome, measured at 6 weeks post randomisation,
will be analysed using linear multivariable regression
correcting for baseline 24- h PWT, the stratification de-
sign variables and other prognostic variables; all models
will include a random effect for CH. The statistical ana-
lysis of the primary outcome will be by intention-to-
treat (ITT); the effects of compliance with treatment will
be explored using causal models to examine if the allo-
cation to treatment impacts on participant adherence
and fidelity fitting of the electrodes. Secondary outcomes
will be analysed using a similar strategy employing gen-
eralised linear models suitable for the outcome. All
treatment effects will be derived from these models and
presented with 95% CIs. All analyses will be performed
and reported in accordance with the Consolidated
Standards of Reporting Trials (CONSORT) statement
and the ICH E9 ‘Statistical Principles in Clinical Trials’
[45]. The main analysis will be performed at the end of
the trial when the 18 weeks follow-up has been
completed.
Qualitative research analysis
For the three sets of qualitative interview data, separate
Framework analyses will be undertaken with the support of
QSR NVivo (version 10) data management and analysis
software. This method permits identification and cross-
classification of variables directly from digital transcriptions.
The analytic process will consist of identifying key concepts
and themes and mapping their range and diversity, followed
by a process of interpretation where patterns of association
will be investigated and possible reasons for these explored.
In achieving this, all transcripts will be summarised, charted
and coded for recurrent themes. Specific analytic intentions
are associated with each of the three interview data sets.
For residents/family carer interviews, the framework
will be developed to explore the elements of perceived
impact and acceptability of TPTNS as a therapeutic
intervention, by residents and family carers, in both the
short-term and for the longer-term.
For the CH staff, the focus group and individual inter-
view framework will highlight the experience of CH staff
in developing their new skill sets and the facilitators and
challenges they experience implementing them into rou-
tine practice. The elements of the Capability, Opportun-
ity, Motivation and Behaviour (COM-B) model which
formed the theoretical underpinning of the staff inter-
view schedule will be key concepts in this framework.
For the CH managers, the focus of the framework for
analysing the CH managers’ interviews will be the cul-
tural, economic, strategic and quality impacts associated
with participating in the trial and implications for imple-
mentation and sustainability at the organisational level.
The coherence, transparency and validity of the interpre-
tations from these three different framework analyses will
be assessed through regular iterative discussion between
the Research Assistant with qualitative research experience
and the study team members with qualitative expertise.
Interim analyses
An independent Data Monitoring and Ethics Committee
(DMEC) will review confidential interim analyses of ac-
cumulating data at its discretion, but at least annually.
There are no formal stopping rules.
Methods for additional analyses (e.g. subgroup analyses)
Planned subgroup analyses
Subgroup analyses will be carried out accordingly by:
 Gender
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 UI severity
 Dependency in toilet use
 Cognitive status
 Falls status.
The threshold for statistical significance for the subgroup
analyses will be 0.01, reflecting the number of subgroup
comparisons being made. Heterogeneity of treatment
effects amongst subgroups will be tested for using the
appropriate subgroup by treatment group interactions.
Process evaluation data analysis
Process evaluation data analysis will address adherence to
the stimulation programme by group, at 6 weeks post
randomisation, the end of the stimulation programme.
Characteristics of residents and the stimulation
programme received will be described using appropriate
summary measures, and the proportion who received the
therapeutic minimum (> 8 stimulation sessions) and the full
12-session programme will be presented. Overall fidelity to
the allocated group will also be assessed and presented to
illuminate resident elements of the outcome analysis,
including total stimulation time, mean intensity of stimula-
tion and accuracy of electrodeposition. Stimulation diaries
will be analysed to inform understanding of when, how and
who delivers the electrical stimulation in practice.
Economic evaluation
The economic evaluation will compare the costs and
outcomes of TPTNS compared with usual continence
care pathways and present these in a cost consequence
analysis. Unit costs will be attached to the individual re-
sources identified in the RUQ (Additional file 2) using
standard sources (including National Health Service
[NHS] Reference Costs, Unit Costs of Health and Social
Care and British National Formulary [37, 46, 47]). Staff
training time will be costed using the appropriate pay
scales for each site. The costs of the trainer and the ma-
terials (TPTNS machines, handbook and training DVD)
will be based on the market rates for these items. Data
on costs will not be combined directly with the primary
study outcome, as it is likely that this will not provide a
representative reflection of the impact of the TPTNS
intervention on this older group of CH residents. Rele-
vant outcomes, including the trial primary and second-
ary outcomes, along with important issues from the
process evaluation will be presented alongside the costs
in a cost consequence analysis. Here the costs will be
presented alongside the effects, both quantitative and
qualitative, in a disaggregated format to allow flexibility
in presenting which costs/effects are relevant to different
stakeholders.
Methods in analysis to handle protocol non-adherence
and any statistical methods to handle missing data
Analysis will be by the ITT method. It is not currently
planned to impute missing values, but multiple imputation
or other strategies within sensitivity analysis may be con-
sidered (see the section on Statistical methods for primary
and secondary outcomes). These will be pre-specified in
the SAP.
Plans to give access to the full protocol, participant-level
data and statistical code
The full current protocol (version 2.0) is provided as
Additional file 1 to this document. Anyone interested in
other data or documentation should contact the corre-
sponding author.
Oversight and monitoring
Composition of the coordinating centre and Trial Steering
Committee
The trial office will be based in the School of Health and
Life Sciences, Glasgow Caledonian University, providing
day-to-day support for the trial. The local PI and RRA in
each site will be responsible for all aspects of local organisa-
tion, including identifying potential recruits and taking
consent. The trial will be supervised by the Project Manage-
ment Group (PMG), which will meet every 3 months. The
PMG will comprise grant holders and representatives from
the trial office and CHaRT. A Trial Steering Committee
(TSC), with six independent members, will meet four times
over the course of the trial to oversee conduct and progress.
A Stakeholder and Public Involvement Group (SPIG) will
meet every 6 to 9 months to advise on trial processes and
acceptability, and also to support interpretation and
dissemination of findings.
Composition of the data monitoring committee, its role
and reporting structure
A DMEC will oversee the safety of subjects in the trial.
The committee will meet regularly to monitor the trial
data and make recommendations as to any required
modifications to the protocol or the termination of all or
part of the trial.
Adverse event reporting and harms
In this trial, all adverse events (AEs) or serious adverse
events (SAEs) occurring during an electrical stimulation
(treatment/sham) session, or while equipment is attached
to the resident’s leg, or during data collection periods will
be recorded. Given the previous established safety profile
of TPTNS, SAEs are not anticipated. In this trial the
following related minor AEs are potentially expected:
 Transient skin redness at electrode sites
 Minor itch at electrode sites.
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All AEs and SAEs will be assessed for expectedness,
seriousness, severity and causality and will be reported
to the DMEC and relevant regulatory bodies as required.
Frequency and plans for auditing trial conduct
Three monthly PMG meetings facilitate review of trial
conduct. The TSC and DMEC will also meet to review
conduct throughout the trial period (four times and
three times respectively).
Plans for communicating important protocol
amendments to relevant parties (e.g. trial participants,
ethical committees)
The Investigators will conduct the trial in compliance
with the protocol given favourable opinion by the Re-
search Ethics Committee(s) (RECs). Any amendment to
the trial will be approved by the Sponsor and funder be-
fore application to the RECs, except in the case of im-
mediate safety measures, when the Sponsor will be
notified as soon as possible. Any deviations from the
protocol will be fully documented using a breach report
form. The CHs will be notified of any protocol amend-
ments, and a copy of the revised protocol will be sent to
the PI to add to the Investigator Site File.
Dissemination plans
The authors plan to publish the findings in a range of
practice-focused journals and publications and make use
of social media to enable rapid dissemination of not only
the research results but also information on training and
implementing TPTNS into practice, if the results indi-
cate it is effective. Short, plain English summaries will be
prepared to disseminate the findings to user groups and
members of the public through websites, newsletters and
social media.
Discussion
UI is highly prevalent in residential and nursing CHs and
has a profound impact on dignity and quality of life [2].
Currently, CHs use a containment approach to managing
UI, predominantly using absorbent pads [8]. These are not
only uncomfortable and undignified for the individual but
are costly to the CH and health service providers. Anti-
cholinergic drugs can also be used to treat UI, but they may
have significant adverse effects in older adults and can ad-
versely interact with drugs used to treat dementia [21].
TPTNS is a non-invasive intervention that has demon-
strated effectiveness at reducing UI in adults [23]. How-
ever, there is a lack of evidence-based research into the
safety, acceptability and effectiveness of its use in frail
older adults. The ELECTRIC trial will test the feasibility
and effectiveness of CH staff delivering TPTNS to adults
in CHs. Economic evaluation will assess the costs of pro-
viding a programme of TPTNS, and the process evalu-
ation will provide valuable information on the experiences
of TPTNS from the point of view of CH residents, family
members, CH staff and managers.
Should TPTNS be shown to be an effective and accept-
able treatment for UI in older adults in CHs, it will provide
a safe, low-cost and dignified alternative to the current
standard approach of containment and medication.
Trial status
The ELECTRIC trial is currently recruiting in five UK
CHs and has completed recruitment in 38 homes. The
first patient was randomised in February 2018, with
current recruitment at 371 participants. Recruitment is
due to be completed at the end of July 2019, and follow-
up will be completed by the end of December 2019. The
TSC and DMEC have convened three times. For updates
see ClinicalTrials.gov and the ELECTRIC trial website
[48]. The current version of the trial protocol (version
2.0) is provided in Additional file 1 and administrative
information is provided in Table 3.
Table 3 Administrative information
Trial registration with registry that adheres
to World Health Organization trial
registration data set
ISRCTN98415244
NCT03248362 (Clinical trial.gov number)
Protocol version Version 2.0; 27.08.18
Funding National Institute for Health Research, Health
Technology Assessment programme, project
number HTA 15/130/73
Name and contact information
for the trial Sponsor
Professor Kay Currie, Associate Dean, Research
and Professor of Nursing, School of Health and
Life Sciences, Glasgow Caledonian University,
Cowcaddens Road, Glasgow, G4 0BA, UK
Role of Sponsor The Sponsor played no part in study design;
collection, management, analysis, and
interpretation of data; writing of the report;
or the decision to submit the report for
publication
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Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-3723-7.
Additional file 1. Current version of trial protocol.
Additional file 2. Resource Use Questionnaire designed for the
ELECTRIC trial.
Additional file 3. SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents.
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